Anfoe 6000 IU

Anfoe 6000IU injection comprises active ingredients such as Recombinant human erythropoietin alfa/epoetin alfa. This medication is classified as an erythropoiesis-stimulating agent (ESA). It is utilized to treat anemia resulting from chronic kidney disease (CKD), cancer chemotherapy, or the treatment of HIV infection with zidovudine. Additionally, it minimizes the necessity for red blood cell transfusions in patients who are at a heightened risk of blood loss due to scheduled surgeries or other medical procedures.

Anfoe 6000IU injection is contraindicated in individuals with hypersensitivity to the drug or any of its components, uncontrolled hypertension, active thrombotic microangiopathy (TMA), pure red cell aplasia (PRCA), uncontrolled seizures, pregnancy, or lactation. Caution is advised when administering this medication to patients with a history of blood clots, cardiovascular disease, stroke, renal disease, hepatic disease, thalassemia, sickle cell anemia, myelodysplastic syndrome, leukemia, or cancer. It should only be prescribed to children under 18 if the potential benefits surpass the associated risks. Older adults receiving this medication should be monitored closely for adverse effects. Prior to initiating treatment with Anfoe 6000IU injection, it is crucial to consult with your healthcare provider regarding the associated risks and benefits.